Broken Business or Temporary Headwinds? Novo Nordisk Stock Explained

Описание: Novo Nordisk has sold off over 60% as they faced multiple headwinds from competition, the FDA placing their key ingredient on the shortage list, to manufacturing issues. However, Novo Nordisk came out with a blockbuster drug for a market that is barely penetrated. In this video we break down the GLP1 market and go into depth into what happened with them and potential future growth opportunities.

I worked at Goldman Sachs and an investment fund that managed hundreds of billions of dollars. In this channel I will teach you everything I know, including how to analyze a business, how to invest, the differences between bad and good businesses, and other finance topics.

Follow us to learn 1) how to become a better investor and 2) how to analyze and understand business!

~*~
Chapters

0:00 — Blockbuster Success
1:00 — Setbacks
2:51 — The Incretin Market
9:56 — Why Down 60% Still?
12:28 — Upside
18:05 — New Threats
21:41 — Other Risks


~*~*~*~*~*~

Drew Cohen runs an investment research firm that caters to professional investor and hedge funds. You can find out more about it at www.SpeedwellResearch.com

Drew also has a podcast with Speedwell Research called The Synopsis. The Synopsis is aimed toward professional investors and covers in-depth specific publicly traded companies.

Follow the Podcast on Spotify here: https://open.spotify.com/show/3lGqHRK...

Follow the Podcast on Apple here: https://podcasts.apple.com/us/podcast...


~*~*~*~*~*~

Nothing here is financial advice. See channel disclaimers.

~*~*~*~*~*~

#investing #stockmarket #finance